RESUMO
BACKGROUND: While several traditional observational studies have suggested associations between gut microbiota and asthma, these studies are limited by factors such as participant selection bias, confounders, and reverse causality. Therefore, the causal relationship between gut microbiota and asthma remains uncertain. METHODS: We performed two-sample bi-directional Mendelian randomization (MR) analysis to investigate the potential causal relationships between gut microbiota and asthma as well as its phenotypes. We also conducted MR analysis to evaluate the causal effect of gut metabolites on asthma. Genetic variants for gut microbiota were obtained from the MiBioGen consortium, GWAS summary statistics for metabolites from the TwinsUK study and KORA study, and GWAS summary statistics for asthma from the FinnGen consortium. The causal associations between gut microbiota, gut metabolites and asthma were examined using inverse variance weighted, maximum likelihood, MR-Egger, weighted median, and weighted model and further validated by MR-Egger intercept test, Cochran's Q test, and "leave-one-out" sensitivity analysis. RESULTS: We identified nine gut microbes whose genetically predicted relative abundance causally impacted asthma risk. After FDR correction, significant causal relationships were observed for two of these microbes, namely the class Bacilli (OR = 0.84, 95%CI = 0.76-0.94, p = 1.98 × 10-3) and the order Lactobacillales (OR = 0.83, 95%CI = 0.74-0.94, p = 1.92 × 10-3). Additionally, in a reverse MR analysis, we observed a causal effect of genetically predicted asthma risk on the abundance of nine gut microbes, but these associations were no longer significant after FDR correction. No significant causal effect of gut metabolites was found on asthma. CONCLUSIONS: Our study provides insights into the development mechanism of microbiota-mediated asthma, as well as into the prevention and treatment of asthma through targeting specific gut microbiota.
Assuntos
Asma , Microbioma Gastrointestinal , Microbiota , Humanos , Microbioma Gastrointestinal/genética , Análise da Randomização Mendeliana , Asma/genética , Nonoxinol , Estudo de Associação Genômica AmplaRESUMO
Urban waterlogging and the deterioration of receiving water quality caused by stormwater runoff have become increasingly significant problems. Based on the concept of combining grey and green infrastructure, a combined permeable concrete pavement (PCP) and constructed wetland (CW) system has been developed to treat stormwater runoff and enable on-site reuse. The results showed that the removal rate of suspended solids (SS) by PCP ranged from 96.61 to 99.20%; however, the chemical oxygen demand (COD), total nitrogen (TN), and total phosphorus (TP) concentrations in the effluent did not meet the standards required for rainwater reuse. For the combined PCP-CW system, the removal rates of COD, TN and TP by the CW were 48.45-75.12%, 47.26-53.05%, and 59.04-75.28%, respectively, under different hydraulic loading (HL) rates; thus, the effluent TN concentrations did not consistently meet the reuse standards. Further optimization of aeration in different parts of the CW revealed that aeration in the middle and front sections of the wetland had the most significant effect on pollutant removal, under which the TN concentrations in the effluent met the standard required for reuse. The effluent from the combined PCP-CW system was able to fully meet the stormwater reuse standards under these optimized conditions, and the reuse of urban stormwater runoff can therefore be realized.
Assuntos
Poluentes Ambientais , Áreas Alagadas , Nitrogênio , Fósforo , Qualidade da ÁguaRESUMO
BACKGROUND Heat shock protein-90 alpha (HSP90a) is more abundant in non-small-cell lung cancer (NSCLC) patients than in control individuals. However, whether it can reflect chemotherapy efficacy remains unknown. This study aimed to investigate the association of HSP90a with chemotherapy in advanced NSCLC. MATERIAL AND METHODS We retrospectively evaluated data from patients admitted to the Department of Respiratory Medicine, Shaoxing People's Hospital, from September 2016 to September 2018 with stage IIIB or IV NSCLC and administered 4 cycles of third-generation platinum-based combination chemotherapy (2 drugs simultaneously). Based on the RECIST1.1 criteria, complete remission (CR), partial response (PR), and stable disease (SD) in 60 cases were determined before and after chemotherapy. Before chemotherapy and after 1, 2, and 4 cycles of chemotherapy, plasma HSP90alpha levels were quantitated by ELISA. Chest CT was performed before and after 2 and 4 cycles of chemotherapy. RESULTS After 1-4 cycles of chemotherapy, plasma HSP90alpha levels were significantly lower than pre-chemotherapy levels (P<0.05). The sums of the longest tumor diameters after 2 and 4 cycles of chemotherapy were decreased compared with pre-chemotherapy values (P<0.05). Plasma HSP90alpha levels and tumor size showed no significant correlation before and after chemotherapy (r=0.244, P=0.06). CONCLUSIONS Plasma HSP90alpha can be considered a valuable predictor of early chemotherapy effectiveness in advanced NSCLC, and is positively correlated with tumor remission after chemotherapy. However, plasma HSP90alpha level is not correlated with tumor diameter and pathological type.
Assuntos
Biomarcadores Tumorais/sangue , Carcinoma Pulmonar de Células não Pequenas/sangue , Proteínas de Choque Térmico HSP90/sangue , Neoplasias Pulmonares/sangue , Idoso , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/patologia , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Critérios de Avaliação de Resposta em Tumores SólidosRESUMO
Constructed wetland-microbial fuel cell (CW-MFC) has attracted much attention because of its dual functions of wastewater treatment and energy recovery. However, its performance in treating high-concentration wastewater is degraded by the decreased dissolved oxygen at the cathode and insufficient electron acceptors. In this study, two CW-MFC systems with cathodic aeration were connected in series to investigate the effects of aeration rate and hydraulic retention time (HRT) on the removal of pollutants and the performance of electricity production in high-concentration wastewater. Results showed that aeration enhanced NH4+-N and TP removal by 45.0-49.8% and 11.5-18.0%, compared with the unaerated condition, respectively. Meanwhile, no significant change regarding COD removal was observed. Aeration enhances the output voltage and power density of the system, especially the first stage CW-MFC, which improved the power production performance by 1 to 2 orders-of-magnitude. Increasing HRT improves the system's pollutant treatment efficiency and power generation performance for high-concentration wastewater. Still, the extension of HRT to 2 days will not contribute much to improving the removal efficiency. Under optimized conditions, the maximum total removal rates of COD, NH4+-N, and TP for the two-stage tandem CW-MFC system were 99.3 ± 0.2%, 92.4 ± 1.6%, and 79.5 ± 3.4%, respectively. Meanwhile, the maximum output voltage and maximum power density of the first-stage CW-MFC were 405 mV and 138.0 mW/m3, respectively. In contrast, the maximum output voltage and maximum power density of the second stage are 105 mV and 14.7 mW/m3, respectively.
Assuntos
Fontes de Energia Bioelétrica , Águas Residuárias , Áreas Alagadas , Eletricidade , EletrodosRESUMO
OBJECTIVE: To observe the time course of interleukin (IL)-21 and related cytokines expression in rats with experimental autoimmune myocarditis (EAM). METHODS: Antigen was prepared with an emulsion of porcine cardiac myosin in complete Freund's adjuvant, plus Mycobacterium tuberculosis H37Ra strain. EAM model was made by hypodermic injection of myosin in hind legs of Lewis rats.mRNA expression of IL-21 and related cytokines (IL-21R, IL-17, TGF-ß, IL-6) in different tissues (heart, liver, spleen, kidney) were determined at 2 weeks after immunization by RT-PCR and quantitative real-time RT-PCR. Furthermore, the time course of IL-21 and related cytokines expression in the acute phase of EAM (2 w, 3 w, 4 w) was determined by quantitative real-time RT-PCR, and IL-21, IL-17 protein expression was determined by Western blot and ELISA. The location of IL-21R was examined by immunohistochemistry at 2 w after immunization. RESULTS: Histopathology examination evidenced abundant mononuclear cells in the myocardium of 2 weeks EAM rats. Fibrosis and multinucleated giant cells were observed in the myocardium of 3 weeks EAM rats. Inflammation was reduced and large amount of fibrosis could be found in 4 weeks EAM rats. The heart weight/body weight ratio in normal, EAM 2 w, 3 w, 4 w group was (3.011 ± 0.117) mg/g, (4.736 ± 1.279) mg/g, (7.200 ± 0.308) mg/g and (4.622 ± 0.978) mg/g respectively. IL-21 mainly expressed in heart and spleen, IL-21R, IL-17, TGF-ß mainly expressed in spleen, and IL-17, IL-6 mainly expressed in heart of EAM rats. IL-21R mainly distributed in cardiomyocytes of 2 weeks EAM rats. In line with pathological EAM course, the expression of IL-21 and related cytokines peaked at 2 weeks and then returned to normal at 4 weeks after immunization. CONCLUSION: IL-21 and related cytokines were involved in the pathological process of EAM, upregulated IL-21 expression might promote Th17 cell differentiation and enhance Th17 cell secretion.
Assuntos
Doenças Autoimunes/imunologia , Interleucinas/imunologia , Miocardite/imunologia , Miocárdio/imunologia , Animais , Doenças Autoimunes/patologia , Modelos Animais de Doenças , Interleucina-17/imunologia , Interleucina-6/imunologia , Masculino , Miocardite/patologia , Miocárdio/patologia , Ratos , Ratos Endogâmicos Lew , Células Th17/citologia , Células Th17/imunologia , Fator de Crescimento Transformador beta/imunologiaRESUMO
Sustainable viral suppression with hepatitis B surface antigen (HBsAg) loss is the new treatment goal for chronic hepatitis B (CHB). The role of antibodies in therapies for persistent hepatitis B virus (HBV) infection has received constant attention. While immunotherapy holds great promise, challenges for the antibody-based prevention and control of HBV in CHB include broad HBV antigenic diversity and the need for long-term viral suppression. In this study, we identified a new anti-HBsAg nanobody (Nb), 125s, isolated from HBsAg-immunized alpaca and confirmed its excellent potency in HBsAg clearance and broad-spectrum therapeutic activity against three HBV subtypes in vivo. In addition, we characterized a novel epitope at the C-terminus of the HBsAg surface motif from amino acids 157 to 174. A 125s-based long-term passive immunization program was efficacious at HBsAg clearance and inducing cellular immune responses, offering a promising outlook for CHB immunotherapy.
Assuntos
Hepatite B Crônica , Hepatite B , DNA Viral , Anticorpos Anti-Hepatite B , Antígenos de Superfície da Hepatite B , Vírus da Hepatite B/genética , Hepatite B Crônica/tratamento farmacológico , HumanosRESUMO
Influenza A viruses pose a significant threat globally each year, underscoring the need for a vaccine- or antiviral-based broad-protection strategy. Here, we describe a chimeric monoclonal antibody, C12H5, that offers neutralization against seasonal and pandemic H1N1 viruses, and cross-protection against some H5N1 viruses. Notably, C12H5 mAb offers broad neutralizing activity against H1N1 and H5N1 viruses by controlling virus entry and egress, and offers protection against H1N1 and H5N1 viral challenge in vivo. Through structural analyses, we show that C12H5 engages hemagglutinin (HA), the major surface glycoprotein on influenza, at a distinct epitope overlapping the receptor binding site and covering the 140-loop. We identified eight highly conserved (~90%) residues that are essential for broad H1N1 recognition, with evidence of tolerance for Asp or Glu at position 190; this site is a molecular determinant for human or avian host-specific recognition and this tolerance endows C12H5 with cross-neutralization potential. Our results could benefit the development of antiviral drugs and the design of broad-protection influenza vaccines.
Assuntos
Vírus da Influenza A Subtipo H1N1 , Virus da Influenza A Subtipo H5N1 , Vacinas contra Influenza , Influenza Humana , Infecções por Orthomyxoviridae , Anticorpos Monoclonais , Anticorpos Neutralizantes , Anticorpos Antivirais , Sítios de Ligação , Anticorpos Amplamente Neutralizantes , Glicoproteínas de Hemaglutininação de Vírus da Influenza , HumanosRESUMO
ABSTRACT: The PITX gene family of transcription factors have been reported to regulate the development of multiple organs. This study was designed to investigate the role of PITXs in lung adenocarcinoma (LUAD).In this study, the transcriptional levels of the 3 identified PITXs in patients with LUAD were examined using the gene expression profiling interactive analysis interactive web server. Meanwhile, the immunohistochemical data of the 3 PITXs were obtained in the Human Protein Atlas website, and western blotting was additionally conducted for further verification. Moreover, the association between the levels of PITXs and the stage plot as well as overall survival of patients with LUAD was analyzed.We found that the mRNA and protein levels of PITX1 and PITX2 were higher in LUAD tissues than those in normal lung tissues, while those of PITX3 displayed no significant differences. Additionally, PITX1 and PITX3 were found to be significantly associated with the stage of LUAD. The Kaplan-Meier Plot showed that the high level of PITX1 conferred a better overall survival of patients with LUAD while the high level of PITX3 was associated with poor prognosis.Our study implied that PITX1 and PITX3 are potential targets of precision therapy for patients with LUAD while PITX1 and PITX2 are regarded as novel biomarkers for the diagnosis of LUAD.
Assuntos
Adenocarcinoma de Pulmão/patologia , Neoplasias Pulmonares/patologia , Fatores de Transcrição Box Pareados/genética , Biomarcadores Tumorais , Perfilação da Expressão Gênica , Regulação Neoplásica da Expressão Gênica , Proteínas de Homeodomínio/genética , Humanos , Estimativa de Kaplan-Meier , Prognóstico , RNA Mensageiro , Fatores de Transcrição/genética , Proteína Homeobox PITX2RESUMO
BACKGROUND: We have previously obtained a mouse anti-hepatitis B surface antigen (HBsAg) antibody E6F6 with long-lasting serum HBsAg clearance effects. The E6F6 epitope-based protein CR-T3-SEQ13 (HBsAg aa 113-135) vaccination therapy in cynomolgus monkeys induced long-term polyclonal antibodies-mediated clearance of HBsAg in the HBV transgenic (HBV-Tg) mice. METHODS: We isolated monoclonal antibodies from CR-T3-SEQ13 vaccinated cynomolgus monkeys, compared their therapeutic effects with E6F6, identified their epitopes on HBsAg, determined the pharmacokinetics and studied their physical property. RESULTS: A panel of anti-HBsAg mAbs was generated through memory B cell stimulatory culture. Two lead monkey-human chimeric antibodies, C1-23 and C3-23, effectively suppressed HBsAg and HBV DNA in HBV-Tg mice. The humanized antibodies and humanized-mouse reverse chimeric antibodies of two antibodies exhibited comparable HBsAg clearance and viral suppression efficacy as those versions of E6F6 in HBV-Tg mice. Humanized antibody hu1-23 exhibited more efficacy HBsAg-suppressing effects than huE6F6-1 and hu3-23 in HBV-Tg mice at dose levels of 10 and 20 mg/kg. Evaluation of the binding sites indicates that the epitope recognized by hu1-23 is located in HBsAg aa 118-125 and 121-125 for hu3-23. Physical property study revealed that hu1-23 and hu3-23 are stable enough for further development as a drug candidate. CONCLUSIONS: Our data suggest that the CR-T3-SEQ13 protein is a promising HBV therapeutic vaccine candidate, and hu1-23 and hu3-23 are therapeutic candidates for the treatment of chronic hepatitis b. Moreover, the generation of antibodies from the epitope-based vaccinated subjects may be an alternative approach for novel antibody drug discovery.
RESUMO
Excessive activation and proliferation of inflammatory cell and uncontrolled release of cytokines and chemokines, also known as cytokine storm, is considered to be the main cause of sepsis. Accumulating evidence has indicated that autophagy may play an important role in regulating immune response and controlling excessive inflammation. Recent studies have showed that minocycline has immunomodulatory effects on cytokine and chemokine production. It has also been reported that minocycline can induce autophagy, suggesting that autophagy may be involved in the process of minocycline regulating inflammation and immune response. However, the precise mechanism is unclear. In the present study, we used enzyme-linked immunosorbent assays (ELISA) to measure the production of cytokines following minocycline treatment of lipopolysaccharide- (LPS-) stimulated THP-1 cells. Western blotting analysis was performed to confirm autophagy and the mTOR signal pathway. Cell proliferation was measured by WST-1 cell proliferation assay. We demonstrated that LPS induced autophagy in a tumor necrosis factor- (TNF-) α-mediated manner, and simultaneously, LPS induced the release of TNF-α to trigger inflammation and activated mammalian target of rapamycin (mTOR) to potentiate cell proliferation. Minocycline, which induces autophagy by inhibiting mTOR, suppresses cytokine production and cell proliferation and protects THP-1 cells from LPS toxicity. Further study demonstrated that there might be an intimate crosstalk between the inhibitor kappa B kinase (IKK)/nuclear factor-kappa B (NF-κB) signaling pathway and autophagy flux in modification of inflammatory responses. In addition, rapamycin, the mTOR inhibitor, has cooperative effect with minocycline on suppression of TNF-α release and induction of autophagy by repressing mTOR. Our data brought a novel clue to evaluate minocycline using as a potential therapeutic medicine for sepsis.
Assuntos
Antibacterianos/farmacologia , Autofagia , Proliferação de Células , Lipopolissacarídeos/farmacologia , Minociclina/farmacologia , Monócitos/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Citocinas/metabolismo , Humanos , Monócitos/metabolismo , Monócitos/patologia , NF-kappa B/metabolismo , Serina-Treonina Quinases TOR/metabolismo , Fator de Necrose Tumoral alfa/metabolismoRESUMO
We have reported that E6F6, a mouse monoclonal antibody, is a promising treatment option for patients with chronic hepatitis B (CHB). A humanized E6F6 antibody B11 with affinity loss was obtained by CDR-grafting approach. To address this issue, in silico affinity maturation through scanning mutagenesis using CHARMM force field methods was performed on an predicted immune complex model of the B11:HBsAg. We chose four variants with top increased interaction energy for further characterization. The antibody huE6F6-1 within two point mutations (Heavy Chain: Asp65Val; His66Leu) was identified to restore the parental antibody's high binding affinity, neutralization activity, and potent efficacy of viral suppression in vivo. Crystal structure (1.8 Å resolution) based molecular docking proved more stabilized and compact hydrogen bond interactions formed in huE6F6-1.The smaller and dispersed HBV immune complexes of huE6F6-1 by electron microscopy suggested it will have the same therapeutic efficacy as the parental E6F6 mAb. Preclinical study and pharmacokinetics of huE6F6-1 demonstrated that it is a stable and desirable lead candidate to improve the clinical management of CHB. Notably, our structure guided approach may facilitate the humanization and affinity maturation of other rodent antibody candidates during drug development.
Assuntos
Anticorpos Monoclonais Humanizados/imunologia , Anticorpos Anti-Hepatite/imunologia , Vírus da Hepatite B/imunologia , Animais , Cristalização , Avaliação Pré-Clínica de Medicamentos , Antígenos de Superfície da Hepatite B/imunologia , Hepatite B Crônica/imunologia , Humanos , Macaca fascicularis , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Simulação de Acoplamento MolecularRESUMO
The ability to selectively kill cancerous cell populations while leaving healthy cells unaffected is a key goal in oncology. The use of nanovesicles (NVs) as chemotherapeutic delivery vehicles has been recently proven successful, yet monotherapy with monomodalities remains a significant limitation for solid tumor treatment. Here, as a proof of principle, a novel cell-membrane-derived NVs that can display full-length monoclonal antibodies (mAbs) is engineered. The high affinity and specificity of mAb for tumor-specific antigens allow these vesicular antibodies (VAs) to selectively deliver a cytotoxic agent to tumor cells and exert potent inhibition effects. These VAs can also regulate the tumor immune microenvironment. They can mediate antibody-dependent cellular cytotoxicity to eradicate tumor cells via recruitment and activation of natural killer cells in the tumor. Upon further encapsulation with chemotherapeutic agents, the VAs show unequaled cooperative effects in chemotherapy and immunotherapy in tumor-bearing mice. As far as it is known, this is the first report of a VA-based multifunctional combination therapy platform. This might lead to additional applications of vesicular antibodies in cancer theranostics.
Assuntos
Anticorpos Monoclonais/imunologia , Portadores de Fármacos/química , Nanopartículas/química , Neoplasias/diagnóstico por imagem , Neoplasias/tratamento farmacológico , Animais , Anticorpos Monoclonais/genética , Antígenos de Neoplasias/imunologia , Antineoplásicos/química , Antineoplásicos/uso terapêutico , Transporte Biológico , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Terapia Combinada/métodos , Doxorrubicina/química , Doxorrubicina/uso terapêutico , Liberação Controlada de Fármacos , Tratamento Farmacológico/métodos , Humanos , Imunoterapia/métodos , Verde de Indocianina/química , Verde de Indocianina/uso terapêutico , Células Matadoras Naturais/efeitos dos fármacos , Camundongos , Camundongos Nus , Terapia de Alvo Molecular/métodos , Tamanho da Partícula , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/química , Fármacos Fotossensibilizantes/uso terapêutico , Propriedades de Superfície , Microambiente Tumoral/efeitos dos fármacosRESUMO
Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the major pathogens of hand, foot and mouth disease (HFMD), which affects children worldwide and is often associated with neurological complications. At present, there is no vaccine or cure available for simultaneous EV71 and CA16 infection, posing a great need to develop novel strategies for the treatment of this disease. Here, we engineered four bispecific antibodies using variable fragments of monoclonal antibodies (mAbs) from EV71- and CA16-specific neutralizing antibodies. The engineered bispecific antibody Bs(scFv)4-IgG-1 exhibits remarkable cross-reactivity against EV71 and CA16 and has a more potent cross-neutralization than its parental antibodies. Furthermore, we showed that Bs(scFv)4-IgG-1 conferred 100% therapeutic efficacy against single or mixed EV71 and CA16 infections in mice. Our study provides important insights into bispecific antibody engineering against enterovirus and will inform new curative treatment options for HFMD.
Assuntos
Anticorpos Biespecíficos/imunologia , Anticorpos Biespecíficos/uso terapêutico , Anticorpos Neutralizantes/uso terapêutico , Anticorpos Antivirais/uso terapêutico , Infecções por Enterovirus/terapia , Doença de Mão, Pé e Boca/terapia , Animais , Reações Cruzadas , Enterovirus/efeitos dos fármacos , Enterovirus Humano A/efeitos dos fármacos , Engenharia Genética , CamundongosRESUMO
Human papillomavirus (HPV) type 16 is the most common type implicated as the etiological agent that causes cervical cancer. The marketed prophylactic vaccines against HPV infection are composed of virus-like particles (VLPs) assembled from the recombinant major capsid protein L1. Elicitation of functional and neutralizing antibodies by vaccination is the mode of action by which the vaccines prevent the viral infection. In this study, a panel of murine mAbs against HPV16 L1 were generated and comprehensively characterized with respect to their mapping to the epitope spectrum on the viral capsid. These mAbs were categorized into five epitope bins by two different methods based on the pairwise cross-inhibition and competition with human polyclonal antibodies. In addition, a preliminary demonstration of the spatial relationship of the epitopes recognized by these mAbs was performed using a cross-blocking assay with a well-characterized human mAb, 26D1. Interestingly, two mAbs recognizing different epitopes were found to act synergistically in the pseudovirion-based neutralization assay (PBNA). To facilitate cross-lab and cross-study comparison, the international standard (IS) serum 05/134 was used to calibrate the mAbs as well as the human serum samples from the HPV16/18 vaccine recipients. The neutralizing mAbs, particularly those that recognizing immunodominant epitopes, would be useful in developing epitope-specific assays for monitoring the vaccine production process and for serological assessment.
Assuntos
Anticorpos Monoclonais/imunologia , Capsídeo/imunologia , Papillomavirus Humano 16/imunologia , Papillomavirus Humano 18/imunologia , Vacinas de Partículas Semelhantes a Vírus/imunologia , Animais , Ensaio de Imunoadsorção Enzimática , Epitopos/imunologia , Humanos , CamundongosRESUMO
Hg(II) is well-known for quenching fluorescence in a distance dependent manner. Nevertheless, when we exposed the fluorophore of a green fluorescent protein (GFP) toward Hg(II), through H148C mutation, the GFP fluorescence could be "lighted up" by Hg(II) down to sub-nM level. The detection linear range is 0.5-3.0 nM for protein solutions at 8.0 nM. The GFPH148C protein displayed a promising selectivity toward Hg(II) and also the cellular imaging capacity. Spectra measurements suggested that the ground-state redistribution of protein contributed to the fluorescence enhancement, which was found not limited to Hg(II), and thus presented an opening for building a pool of GFP-based chemosensors toward other heavy metal ions.
Assuntos
Escherichia coli/citologia , Corantes Fluorescentes/química , Proteínas de Fluorescência Verde/química , Mercúrio/análise , Imagem Óptica , Cátions Bivalentes/análise , Escherichia coli/química , Escherichia coli/genética , Corantes Fluorescentes/metabolismo , Proteínas de Fluorescência Verde/genética , Microscopia de Fluorescência , Mutagênese Sítio-Dirigida , Mutação Puntual , Espectrometria de Fluorescência , Regulação para CimaRESUMO
BACKGROUND: We have raised a panel of broad spectrum neutralizing monoclonal antibodies against the highly pathogenic H5N1 avian influenza virus, which neutralize the infectivity of, and afford protection against infection by, most of the major genetic groups of the virus evolved since 1997. Peptide mimics reactive with one of these broad spectrum H5N1 neutralizing antibodies, 8H5, were identified from random phage display libraries. METHOD: The amino acid residues of the most reactive 12mer peptide, p125 (DTPLTTAALRLV), were randomly substituted to improve its mimicry of the natural 8H5 epitope. RESULT: 133 reactive peptides with unique amino acid sequences were identified from 5 sub-libraries of p125. Four residues (2,4,5.9) of the parental peptide were preserved among all the derived peptides and probably essential for 8H5 binding. These are interspersed among four other residues (1,3,8,10), which exhibit restricted substitution and probably could contribute to binding, and another four (6,7,11,12) which could be randomly substituted and probably are not essential for binding. One peptide, V-1b, derived by substituting 5 of the latter residues is the most reactive and has a binding constant of 3.16×10(-9) M, which is 38 fold higher than the affinity of the parental p125. Immunoassay produced with this peptide is specifically reactive with 8H5 but not also the other related broad spectrum H5N1 avian influenza virus neutralizing antibodies. Serum samples from 29 chickens infected with H5N1 avian influenza virus gave a positive result by this assay and those from 12 uninfected animals gave a negative test result. CONCLUSION: The immunoassay produced with the 12 mer peptide,V1-b, is specific for the natural 8H5 epitope and can be used for detection of antibody against the broad spectrum neutralization site of H5N1 avian influenza virus.
Assuntos
Anticorpos Neutralizantes/análise , Anticorpos Neutralizantes/imunologia , Materiais Biomiméticos , Ensaio de Imunoadsorção Enzimática/métodos , Epitopos/imunologia , Virus da Influenza A Subtipo H5N1/imunologia , Oligopeptídeos/imunologia , Sequência de Aminoácidos , Substituição de Aminoácidos , Animais , Especificidade de Anticorpos , Materiais Biomiméticos/química , Oligopeptídeos/química , Oligopeptídeos/genéticaRESUMO
A sub-library based on peptide mimic 125 was designed and constructed, and 18 phagotopes specifically binding 8H5mAb were isolated. Antisera against three phagotopes, containing peptide 12MH-1, 12MH-5 and 12MH-8 reacted with 3 different H5N1 virus strains, but not with 2 H1N1 and 2 H3N2 viruses by Dot blots. The affinity of 12MH-8 was approximately eight times more than 12MH-1 or 12MH-5 or parent peptide 125. Furthermore, synthesized 12MH-1 and 12MH-8 could block the 8H5mAb binding with 4 H5N1 virus strains via hemagglutinin inhibition. These results suggest that these 3 mimotopes closely mimics the native 8H5 epitopes.